P1, N=174, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2025 --> May 2029 | Trial primary completion date: Dec 2024 --> Aug 2025

6 days ago

Trial completion date • Trial primary completion date • Metastases

Xtandi (enzalutamide) • abiraterone acetate • prednisone • abiraterone decanoate (ASP5541)

3ms

PRL-02-1001: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer (clinicaltrials.gov)

P1, N=174, Recruiting, Astellas Pharma Global Development, Inc. | Phase classification: P1/2 --> P1 | N=100 --> 174

3 months ago

Phase classification • Enrollment change • Metastases

Xtandi (enzalutamide) • abiraterone acetate • prednisone • abiraterone decanoate (ASP5541)

1year

Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide. (ASCO-GU 2024)

PRL-02 was well tolerated. The RP2D of 1260 mg was selected over 1800 mg due to the absence of progesterone rises at 1260 mg. PRL-02 produces durable dose dependent T suppression and associated PSA response.

1 year ago

Clinical • P1/2 data

Xtandi (enzalutamide) • abiraterone decanoate (ASP5541)

almost4years

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer (clinicaltrials.gov)

P1/2, N=45, Not yet recruiting, Propella Therapeutics

almost 4 years ago

Clinical • New P1/2 trial

ALB (Albumin)

abiraterone decanoate (ASP5541)